In a transformative partnership, Carcinotech and PharmaCorp are using 3D bioprinting to create realistic 3D-printed tumors, accelerating cancer research and drug discovery. Specialized materials like biocompatible resins are instrumental in this advancement.
Dr. Ishani Malhotra, Carcinotech’s CEO, noted that their models have garnered significant interest in clinical trials for their realism, providing more accurate results. The partnership has produced specific cancer models like breast, lung, and colon cancer, optimized through Carcinotech’s Carcino3D technology.
PharmaCorp capitalizes on these models for high-throughput drug screenings, fast-tracking drug discovery. “Our 3D-printing capabilities enable swift adaptation to research, improving our drug screening accuracy,” said Dr. Malhotra.
Moreover, PharmaCorp utilizes these 3D-printed tumors in immunotherapy research, incorporating patient-derived immune cells to provide a multi-dimensional research model. The partnership has also innovated in targeted drug delivery, leveraging Carcinotech’s models to significantly enhance delivery precision, raising efficacy rates in tests by up to 80%.
As Carcinotech and PharmaCorp continue to iterate and refine their processes, their collaboration is setting new benchmarks for realism, effectiveness, and technological advancement in cancer research. With an array of projects lined up for the future, this synergistic partnership serves as an exemplar of how 3D-printing technology can be a game-changer in the world of medical research and drug discovery.
